Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer

BACKGROUNDS: EGFR-mutant non-small cell lung cancer (NSCLC) that developed acquired resistance to EGFR-tyrosine kinase (TKI) are potential candidates for programmed death 1 (PD1) inhibitor. RESULTS: TPS≥1% for PD-L1 and low CD8(+) TIL in post-TKI tumor showed a trend for a lower PFS of EGFR-TKIs (14...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae-Jung, Hong, Soon Auck, Kim, Okran, Kim, Seung Joon, Yang, Ji-Hyun, Joung, Eun Kyo, Kang, Jin-Hyoung, Hong, Sook-Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746096/
https://www.ncbi.nlm.nih.gov/pubmed/29296194
http://dx.doi.org/10.18632/oncotarget.22582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746096/
https://www.ncbi.nlm.nih.gov/pubmed/29296194
http://dx.doi.org/10.18632/oncotarget.22582

Ejemplares similares